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Abstract
Background: The traditional view on the relationship between lipid biomarkers and CVD risk has changed during
the last decade. However, it is not clear whether novel lipid biomarkers are able to confer a better predictability of
CVD risk, compared to traditional ones.Under this perspective, the aim of the present work was to evaluate the
predictive ability of blood lipids’ profile on all cause mortality as well as 10-year incidence of CVD, in a sample of
apparently healthy adults of the ATTICA epidemiological study.
Methods: From May 2001 to December 2002, 1514 men and 1528 women (>18 y) without any clinical evidence of any
other chronic disease, at baseline, were enrolled. In 2011–12, the 10-year follow-up was performed in 2583 participants
(85 % follow-up participation rate). Incidence of fatal or non-fatal CVD was defined according to WHO-ICD-10 criteria.
Baseline serum blood lipids’ profile (Total-C, HDL-, non HDL-, LDL-cholesterol, triglycerides (TG), apolipoprotein (Apo)A1
and B, and lipoprotein–(a) levels were also measured.
Results: The 10-year all-cause mortality rate was 5.7 % for men and 2.0 % for women (p = 0.55). The, 10-year CVD
incidence was 19.7 % in men and 11.7 % in women (p < 0.001). Multi-adjusted analysis revealed that TC, non-HDL-C,
TG and TG/HDL-C ratio, were independent predictors of all cause mortality (RR per 1 mg/dL or unit (95 % CI): 1.006
(1.000–1.013), 1.006 (1.000–1.013), 1.002 (1.000–1.004), 1.038 (1.001–1.077), respectively). Moreover, TC, HDL-, LDL-,
non-HDL-cholesterol, TG, apoA1, TC/HDL-C and TG/HDL-C were independently associated with CVD risk. Among all
lipid indices the ratio of apoB/apoA1 demonstrated the best correct reclassification ability, followed by non-HDL-C and
TC/HDL-C ratio (continuous Net Reclassification Index 26.1 and 21.2 %, respectively).
Conclusion: Elevated levels of lipid biomarkers are independently associated with all-cause mortality, as well as CVD
risk. The ratio of apoB/apoA1, followed by non-HDL-C, demonstrated the best correct classification ability of the
developed CVD risk models.
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Background
Cardiovascular disease (CVD) remains one of the major
causes of death world-wide, despite the huge efforts that
have been undertaken the past decades for the clarification
of its pathogenesis and treatment, as well as its prevention
at population and individual level [1]. The identification of
the risk factors that lead to atherosclerosis and their
subsequent modification by lifestyle interventions and
pharmaceutical treatment is the cornerstone of the pre-
vention policies [2]. Large cohort studies have shown
that smoking and dyslipidemia are the two most important
risk factors for myocardial infarction, followed by diabetes,
hypertension and obesity [3]; and most scoring systems
utilize age, gender, systolic blood pressure, smoking sta-
tus, and total cholesterol (TC) or Low Density Lipoprotein
cholesterol (LDL-C) concentration as the main variables of
their algorithms [4–6]. Nowadays, the reduction of LDL
cholesterol levels remains the primary target for the pri-
mary prevention of CVD [7, 8] and this is supported by a
strong body of evidence showing that it is an important
marker of coronary heart disease (CHD) [9]. However, it
has been acknowledged that a high residual CVD risk still
exists, with a considerable proportion of potential CVD
“candidates” being underestimated, and therefore, the
need for the identification of novel biomarkers, especially
of lipid/lipoprotein metabolism, is emerged [10]. More-
over, a high residual risk characterizes people with obesity
or metabolic syndrome, where LDL-C is less predictive for
developing CVD [11]. These people are characterized by
low levels of HDL-C, elevated levels of triglycerides and a
high content of small dense pro-atherogenic apo B lipo-
protein particles [12]. Small dense lipoproteins (which is
estimated by the apoB or non-HDL cholesterol concentra-
tion), penetrate more easily the arterial wall and it seems
that their number rather than their cholesterol content
drives foam cell formation [13]. It is therefore possible
that people with a high content of elevated small dense
lipoprotein particles have near normal LDL-C values
due to the discordance between the apoB particle num-
ber and their cholesterol content. These people will
have an underestimated risk prediction score [14].
Moreover, accumulating evidence from recent epi-
demiological, genetic and biochemical studies changed
the traditional view for the role of HDL-C which seems
to serve as a strong predictor rather than a causative
factor of CVDs [15, 16]. Finally, recent cohort studies
have demonstrated the predictive power of Lp(a) since
its elevated levels correlate to CVD risk in a continuous
and independent manner [17]. It is therefore obvious
that the traditional view on the relationship between
lipid biomarkers and CVD risk has changed during the
last decade. However, it is not clear whether novel lipid
biomarkers (e.g., apoB, apoA1, Lp(a), non-HDL-C) are
able to confer a better predictability of CVD risk,
compared to the more traditional ones (LDL-C, HDL-C
and TGs).
Based on the existing literature, studies evaluating the
predictive ability of a variety of blood lipids/lipoproteins
for CVD incidence are lacking. Under this perspective,
the aim of the present work was to evaluate the predictive
ability of blood lipids’ profile, i.e., TC, LDL-C, HDL-C
non-HDL-C, apoA1, apoB and Lp(a) levels, on all cause
mortality as well as 10-year incidence of CVD, in a sample
of apparently healthy adults of the ATTICA epidemio-
logical study.
Methods
Sampling procedure at baseline examination
The ATTICA study was established during 2001–2002, in
the greater metropolitan area of Athens (that includes 78 %
urban and 22 % rural regions). The sampling procedure an-
ticipated enrolling only one participant per household; it
was random, multistage and based on the age, sex distribu-
tion of the region (as provided in the 2001census). Of the
4056 initially invited individuals, 3042 agreed to participate
at baseline examination (75 % participation rate); 1514 of
the participants were men (18–87 years) and 1528 were
women (18–89 years). All participants were interviewed by
trained personnel (cardiologists, general practitioners, dieti-
cians and nurses) who used a standard questionnaire. Ex-
clusion of CVD at baseline evaluation was performed
through a detailed clinical evaluation by the physicians of
the study, following standard criteria. The examination was
performed in the individuals’ homes or workplaces places.
Lipids and other measurements at baseline examination
The blood samples were collected from the antecubital
vein, between 8 to 10 a.m., in a sitting position after 12 h
of fasting and avoiding of alcohol. Serum for the measure-
ment of blood lipids was harvested immediately after ad-
mission. The biochemical evaluation was carried out in
the same laboratory that followed the criteria of the World
Health Organization Lipid Reference Laboratories. Serum
total cholesterol, HDL-cholesterol and triglycerides were
measured using chromatographic enzymic method in a
Technicon automatic analyser RA-1000 (Dade Behring,
Marburg, Germany). HDL-cholesterol was determined
after precipitation of the Apolipoprotein B containing li-
poproteins with dextran-magnesium-chloride. Non-HDL
cholesterol was calculated by the formula: total cholesterol
minus HDL cholesterol. Lipoprotein (a) was measured by
a latex enhanced turbidimetric immuno-assay. LDL chol-
esterol calculated using the Friedewald formulae: {total
cholesterol} – {HDL cholesterol} – 1/5 (triglycerides) (only
for participants with triglycerides < 400 mg/dL). ApoB and
apoAI were measured by rate immunonephelometry. An
internal quality control was in place for assessing the val-
idity of cholesterol, triglyceride and HDL methods. The
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intra and inter-assay coefficients of variation of cholesterol
levels did not exceed 9 %, triglycerides 4 % and HDL 4 %.
The baseline evaluation also included information about:
age, sex, mean annual income and years of school, assess-
ment of history of hypertension, hypercholesterolemia and
diabetes, family history of CVD, dietary and lifestyle habits
(i.e., smoking status, dietary habits and physical activity sta-
tus). Specifically, smokers were defined those who were
smoking at least one cigarette per day during the past year
or had recently stopped smoking (during a year), while the
rest of the participants were defined as noncurrent-
smokers; the evaluation of the dietary habits was based on
a validated semi-quantitative food-frequency questionnaire
[18], the EPIC-Greek questionnaire, which was kindly pro-
vided by the Unit of Nutrition of Athens Medical School.
The MedDietScore was also applied (range 0–55) to evalu-
ate adherence to the Mediterranean diet [19]. For the evalu-
ation of physical activity status the International Physical
Activity Questionnaire (IPAQ) was used [20], as an index
of weekly energy expenditure using frequency (times per
week), duration (in minutes per time) and intensity of
sports or other habits related to physical activity (in
expended calories per time). Participants who did not
report any physical activities were defined as physically in-
active (sedentary lifestyle). Body mass index (BMI) was
measured as weight (in kilograms) divided by standing
height (in meters squared). Obesity was defined as BMI
greater than 29.9 Kg/m2. Waist (in cm) and hip (in cm) cir-
cumferences were also measured. Arterial blood pressure
(3 recordings) was measured at the end of the baseline
physical examination with subject in sitting position, and
at least 30 min at rest. Participants whose average blood
pressure levels were greater or equal to 140/90 mmHg or
were under antihypertensive medication were classified as
having hypertension. Further details about the aims and
procedures of the ATTICA epidemiological study may be
found elsewhere [21].
Follow-up examination (2011–2012)
During 2011–12, the ATTICA Study’s investigators per-
formed the 10-year follow-up (mean follow-up time 8.41 y).
Of the n = 3042 initially enrolled participants, n = 2583
were found during the follow-up (85 % participation rate).
Of the n = 459 individuals that were lost to follow-up,
n = 224 were not found because of missing or wrong
addresses and telephone numbers that they have provided
at baseline examination and n = 235 because they denied to
be re-examined. In order to participate in the follow-up all
participants were initially appointed through telephone
calls. Afterwards, the investigators approached the allocated
participants and performed a detailed medical evaluation.
Information about participants’: (a) vital status (death from
any cause), (b) development of fatal or non-fatal CVD (i.e.,
myocardial infarction, angina pectoris, other identified
forms of ischemia -WHO-ICD coding 410–414.9, 427.2,
427.6-, heart failure of different types and chronic arrhyth-
mias -WHO-ICD coding 400.0–404.9, 427.0–427.5, 427.9-,
stroke WHO-ICD coding 430–438), was also assessed. Ac-
curate CVD incidence data were obtained for n = 2,020 out
of the 2,583, thus, the analysis for 10-year CVD incidence
was performed for these subjects. Further details about the
follow-up of the ATTICA epidemiological study may be
found elsewhere [22, 23].
Statistical analysis
All cause mortality rates or non-fatal and fatal CVD inci-
dence was calculated as the ratio of new deaths or CVD
cases, respectively, to the number of people participated
in the follow-up. Continuous variables were presented as
mean values ± standard deviation and categorical variables
are presented as frequencies. Associations between cat-
egorical variables were tested using the Pearson’s chi-
square test. The Kruskal-Wallis and the McNemar non-
parametric tests were used to compare continuous factors
and prevalence rates of clinical conditions between base-
line and follow-up examinations. Comparisons between
mean values of normally distributed variables between
those who developed an event and the rest of the partici-
pants were performed using Student’s t-test, after control-
ling for equality of variances using the Levene’s test. The
continuous variables were tested for normality through P-P
plots. For the continuous variables that were not nor-
mally distributed (i.e., triglycerides) the Mann–Whitney
test was applied to evaluate the differences in the distribu-
tions between those who developed an event and the rest
of the participants. The relative risks (RR) of developing an
event during the 10-year period, according to the partici-
pants’ baseline characteristics were estimated using Cox
proportional hazards models. Proportionality of hazards
was graphically assessed by plotting partial residuals against
time. The time to CVD event was recorded on annual
basis. Interactions between age, sex and lipids levels were
tested and Log-rank test was applied to evaluate difference
between genders. Known confounders (i.e., smoking, phys-
ical activity status, BMI, history and management of hyper-
tension, diabetes, hypercholesterolemia and family history
of CVD) were also included in all models. Negelkerke ad-
justed R-square and C-statistic were calculated to evaluate
model’s goodness of fit and classification ability. Harrell’s C
of inverse RR was used as a measure of the predictive
power of the estimated models [24]; Harrell’s C is de-
fined as the proportion of all subject pairs in which
the predictions and outcomes are concordant. Harrell’s C
plays an important role in rank statistics and has been ex-
tensively used for assessing prediction performance in sur-
vival analysis settings. The continuous-Net Reclassification
Improvement (cNRI) was also calculated, according to
Pencina et al., in order to quantify the % of improvement
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in model’s predictive ability after the introduction of vari-
ous blood lipids [25]. All reported p-values are based on
two-sided tests. SPSS version 19 (Statistical Package for
Social Sciences, SPSS Inc, Chicago, IL, USA) and STATA
version 12 (College Station, TX, USA) software were used
for all the statistical calculations.
Results
The 10-year all-cause mortality rate was 3.8 % (n = 73,
5.7 % of men and n = 26, 2.0 % of women had a fatal
event, p = 0.55). The distribution of causes of deaths
was: 51.1 % were due to CVD (i.e., 42.2 % CHD, 4.4 %
stroke and 4.4 % other CVD), 30.0 % were due to cancer,
7.8 % were due to infections (mainly pulmonary), 6.7 %
were accidents and the rest 4.4 % were due to other rea-
sons not identified. The, overall 10-year CVD incidence
was n = 317 (15.7 %) (n = 198, 19.7 % in men and n = 119,
11.7 %in women, p < 0.001). Of the n = 317 CVD events,
46 were fatal (n = 34 men); the 10-year CVD death rate
was 1.8 % (3.4 % for men and 1.2 % for women, p < 0.001).
Blood lipids profile, demographic, clinical and lifestyle
characteristics of the participants according to the 10-year
event status are presented in Table 1. Participants who
developed a CVD event within the 10-year follow-up
were older at baseline examination than subjects who
remained free of the disease (p < 0.001), more likely to be
men (p < 0.001), with lower educational status (p < 0.001),
obese (p < 0.001) and they were away from the Mediterra-
nean diet, as assessed with the MedDietScore (23 ± 7/55 vs.
26 ± 6/55, respectively, p < 0.001). As regards their baseline
clinical profile, subjects who developed CVD were more
likely to be hypertensive (p < 0.001), to have diabetes melli-
tus (p < 0.001) and hypercholesterolemia (p < 0.001), than
CVD-free subjects. Blood lipids levels were also elevated
among subjects who developed a CVD-event.
The association between various lipidaemic markers on
CVD risk as well as on all-cause mortality risk was investi-
gated, independently of several potential confounders (age,
sex, Body Mass Index, physical activity status, smoking,
level of adherence to Mediterranean diet - assessed with
the MedDietScore-, history and management of hyperten-
sion, dyslipidemia and diabetes mellitus and family history
of CVD).
Modelling blood lipids levels and 10-year all cause
mortality
As it can be seen in Table 2 regarding all-cause mortality,
it was observed that for 10 units (mg/dL) or 0.26 units
(mmol/L) increase in TC levels, the 10-year mortality risk
rises by 0.6 % (RR per 1 mg/dL or per 0.026 mmol/L:
Table 1 Characteristics of the ATTICA study’s participants (n = 2020) according to the 10-year fatal or non-fatal incidence of CVD
Status at 10-year follow – up
Baseline CVD event free (n = 1703) CVD events (n = 317) p
Age, yrs 45 ± 14 43 ± 13 58 ± 13 <0.001
Male gender, % 50 % 48 % 63 % <0.001
Years of school 12 ± 4 13 ± 4 10 ± 4 <0.001
Smoking at baseline or before, % 43 % 55 % 57 % 0.462
Physical activity, % 41 % 41 % 41 % 0.999
MedDietScore (0–55) 26 ± 7 26 ± 6 23 ± 7 <0.001
Hypertension, % 30 % 28 % 51 % <0.001
Hypercholesterolemia, % 39 % 40 % 57 % <0.001
Use of lipid-lowering meds, % 25 % 38 % 21 % <0.001
Total cholesterol, mmol/L 4.99 ± 1.09 4.99 ± 1.06 5.33 ± 1.09 <0.001
HDL-cholesterol, mmol/L 1.24 ± 0.39 1.27 ± 0.39 1.16 ± 0.31 <0.001
LDL-cholesterol, mmol/L 3.15 ± 0.96 3.13 ± 0.96 3.39 ± 1.03 <0.001
Apolipoprotein AI, mg/dL 154 ± 27 156 ± 27 150 ± 24 0.001
Apolipoprotein B, mg/dL 108 ± 38 106 ± 42 109 ± 29 <0.001
Triglycerides, mmol/L** 1.13 ± 0.42 1.08 ± 0.41 1.48 ± 0.51 <0.001
Lipoprotein-a, mg/dL** 11 ± 9.5 11 ± 9.5 13 ± 11 0.052
Diabetes, % 7 % 5 % 22 % <0.001
Obesity, % 18 % 17 % 28 % <0.001
Family history of CVD, % 28 % 28 % 32 % 0.297
*p-values for the comparisons between CVD event and event-free group derived using the t-test for age, total, HDL-cholesterol and MedDietScore or Mann–Whitney
non-parametric test (**) for years of school and the rest lipids, while for the comparisons of categorical variables using the chi-square test
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1.006, 95 % Confidence Intervals (CI):1.00, 1.013). The
same effect was revealed for non-HDL cholesterol (RR per
1 mg/dL or per 0.026 mmol/L: 1.006, 95 %CI: 1.00, 1.013),
while for 10 units (mg/dL) or 0.115 units (mmol/L) in-
crease in serum triglycerides, the 10-year mortality risk in-
creased by 0.2 % (RR per 1 mg/dL or per 0.0115 mmol/L:
1.002, 95 % CI: 1.000, 1.004). The only lipidaemic markers
ratio of those tested here, that was significantly associated
with 10-year all-cause mortality was the triglycerides/HDL-
cholesterol ratio, which increased the risk by 3.8 % per 1
unit increase (RR per 1 unit: 1.038, 95 % CI:1.001,1.077).
Modelling blood lipids levels and 10-year CVD event rate
The association between lipid markers and 10-year CVD
incidence was also tested. It was revealed that for 10 units
(mg/dL) or 0.26 units (mmol/L) increase in non-HDL-
cholesterol levels, the 10-year CVD risk increased by 5 %
(RR per 1 mg/dL or per 0.026 mmol/L: 1.005, 95 % CI:
1.001, 1.009), while for 10 units (mg/dL) or 0.115 units
(mmol/L) increase in serum triglycerides, the 10-year
CVD risk increased by 2 % (RR per 1 mg/dL or per
0.0115 mmol/L: 1.002, 95 % CI:1.001, 1.003). Furthermore,
for every unit increase in total cholesterol/HDl-chol-
esterol ratio, the 10-year CVD risk increased by 21.6 %
(RR = 1.216, 95 % CI: 1.092, 1.354) and for every unit
increase in triglycerides/HDL-cholesterol ratio, the 10-
year CVD risk increased by 5.5 % (RR = 1.055, 95 % CI:
1.031, 1.078).
Of those who had already known blood lipids abnormal-
ities (Table 1), 36 % of men and 33 % of women followed
only a dietary medication and 31 % of men and 20 % of
women were under a complimentary lipid-lowering medi-
cation (95 % of them under statin treatment). The use of
lipid-lowering was then taken into account in all models;
Table 2 Results from survival models that evaluated the association of blood lipids and lipoproteins on 10-year all-cause mortality
and CVD incidence, among the ATTICA study participants (n = 2,583)
All-cause mortality CVD incidence
Independent predictor RR 95 % CI RR 95 % CI
Model 1: Total cholesterol (per 1 mg/dL*) 1.006 1.000,1.013 1.003 0.999,1.007
Model 2: HDL cholesterol (per 1 mg/dL) 0.988 0.962,1.015 0.983 0.967,1.000
Model 3: LDL cholesterol (per 1 mg/dL) 1.004 0.996,1.011 1.002 0.998.1.007
Model 4: non-HDL cholesterol (per 1 mg/dL) 1.006 1.000,1.013 1.005 1.001,1.009
Model 5: Triglycerides (per 1 mg/dL) 1.002 1.000,1.004 1.002 1.001,1.003
Model 5: Lipoprotein-a (per 1 mg/dL) 1.004 0.994,1.015 1.003 0.997,1.010
Model 6: Apolipoprotein-A1 (per 1 mg/dL) 0.991 0.978,1.004 0.992 0.985,1.000
Model 7: Apolipoprotein-B (per 1 mg/dL) 1.004 0.997,1.012 1.002 0.998,1.007
Model 8: Total/HDL-cholesterol ratio (per 1 unit) 1.169 0.978,1.387 1.216 1.092,1.354
Model 9: Apolipoprotein-B/-A1 ratio (per 1 unit) 1.560 0.837,2.910 1.389 0.921,2.094
Model 10: Triglycerides/ HDL-cholesterol ratio (per 1 unit) 1.038 1.001,1.077 1.055 1.031,1.078
All models were adjusted for age, sex, BMI, smoking habits, physical activity status, MedDietScore and history and pharmaceutical management of dyslipidemias,
hypertension and diabetes, and family history of CVD at baseline examination. Results are presented as Relative Risk (RR) and 95 % Confidence Interval (CI)
*1 mg/dL corresponds to 0.0259 mmol/L for Total cholesterol, HDL cholesterol, LDL cholesterol, non-HDL cholesterol and to 0.0115 mmol/L for Triglycerides
Table 3 Classification indices from survival models that evaluated
the association of blood lipids and lipoproteins on 10-year CVD
incidence, among the ATTICA study participants (n = 2020)
Independent predictor Adj. R2 Harrell’s C cNRI
Model 1: Total cholesterol
(per 1 mg/dL*)
17.4 % 0.205 10.4 %
Model 2: HDL cholesterol
(per 1 mg/dL)
17.8 % 0.521 12.6 %
Model 3: LDL cholesterol
(per 1 mg/dL)
17.6 % 0.739 11.1 %
Model 4: non-HDL cholesterol
(per 1 mg/dL)
18 % 0.383 21.2 %
Model 5: Triglycerides
(per 1 mg/dL)
17.3 % 0.707 5.0 %
Model 5: Lipoprotein-a
(per 1 mg/dL)
17.6 % 0.562 6.7 %
Model 6: Apolipoprotein-A1
(per 1 mg/dL)
17.9 % 0.271 3.4 %
Model 7: Apolipoprotein-B
(per 1 mg/dL)
17.7 % 0.277 19.7 %
Model 8: Total/HDL-cholesterol
ratio (per 1 unit)
18.5 % 0.901 21 %
Model 9: Apolipoprotein-B/-A1
ratio (per 1 unit)
17.7 % 0.417 26.1 %
Model 10: Triglycerides/HDL-
cholesterol ratio (per 1 unit)
18.2 % 0.616 14.8 %
Model refers to the ones presented in Table 2
cNRI Continuous Net Reclassification Index
*1 mg/dL corresponds to 0.0259 mmol/L for Total cholesterol, HDL cholesterol,
LDL cholesterol, non-HDL cholesterol and to 0.0115 mmol/L for Triglycerides
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no alterations in the aforementioned results were observed
when a variable indicating whether participants dyslipid-
emic adhered to the prescribed medication or not entered
in the models.
Evaluating the predictive ability of lipids and lipoproteins
on 10-year CVD event rate
One of the main goals of the present analysis was to hier-
archy the explanatory ability of lipids levels in predicting
future CVD events, and therefore, to provide useful in-
sights in primary CVD prevention. The model with the
highest explanatory ability was the one included the
total cholesterol/HDL-cholesterol ratio (R-square = 18.5 %),
followed by the model with the triglycerides/HDL-choles-
terol ratio (R-square = 18.2 %) and the model with the non-
HDl-cholesterol (R-square = 18 %), whereas the rest models
had an explanatory ability between 17.3-17.9 %. Regarding
the predictive power of the estimated models, based on
Harrell’s C values it was observed that the best model was
the one contained TC/HDL-C levels, followed by the
model contained LDL-C and the model contained TGs/
HDL-C levels (Tables 3).
Another important issue in the effective risk man-
agement is the accurate prediction of the potential CVD
candidate. Identifying factors that better confer to the ac-
curacy of a risk model allows flexibility in risk management
and improved assessment of overall risk. Thus, regarding
the correct classification rate of the applied CVD risk
models, the model containing the Apolipoprotein-B/-A1
ratio was the one with the best correct reclassification abil-
ity (continuous Net Reclassification Index (cNRI = 26.1 %),
suggesting that addition of this variable in the core model
(i.e., the model without the lipid marker, but with all other
predictors) lead to improved correct reclassification (CVD
event/no-CVD event) of 26 out of 100 participants,
followed by the model with the non-HDL-cholesterol
(cNRI = 21.2 %). The rest of the models correctly re-
classified less than 20 % of the participants to the CVD
event or non-event groups (Table 3).
Discussion
As far as it is known know a comparison of the predictive
ability between lipid biomarkers on total mortality, as well
as CVD incidence, have rarely been tested before, especially
in the Mediterranean region [26, 27]. Taking into account
that the ability of each cardiometabolic risk factor to predict
a future event could be modulated by lifestyle characteris-
tics [28] and genetic background [29, 30], the evaluation of
their predictive ability in various populations is extremely
important for the implementation of public health policies.
Dyslipidemia is considered as one of the most important
risk and prognostic factors for CVD [3, 5, 15, 31]. However,
the high residual risk for CVD [10, 11] led lipid research to
the suggestion of novel surrogate lipid markers, e.g., apoB,
apoA1, non-HDL-C, small dense LDL, LDL particle num-
ber, Lp(a) [32, 33], with conflicting results, implying that
further studies in different populations are still needed.
Moreover, the ability of the aforementioned indices to pre-
dict all cause mortality has not been extensively studied.
Based on a large scale prospective cohort study, it was re-
vealed here that ApoB/A1 ratio, non-HDL cholesterol levels
and TC/HDL-C ratio improved CVD risk models’ predict-
ive ability. Despite the potential limitations of the present
study, the results presented here may confer to better un-
derstanding the role of lipid biomarkers in CVD risk strati-
fication and management, and therefore, could be taken
into consideration by public health care authorities.
Concerning the baseline lipid profile of the study’s par-
ticipants’, it was characterized by raised levels of TC and a
rather high proportion of hypercholesterolemia, but near
normal mean values of HDL-C, TGs, Lp(a) and apolipo-
proteins. Thus, this mild dyslipidemic profile of the cohort
along with the relatively small variability of the lipid levels
between subjects may modest the strength of the observed
association between lipid indices and 10-year CVD risk.
Multi-adjusted models demonstrate that lipid indices,
specifically TC, non-HDL-C, TGs and the ratio TG/
HDL-C, were independent predictors of all cause mor-
tality (Table 2). The positive association between TC
and risk of all cause mortality was also observed in a gen-
eral population cohort from Japan [34], in a middle aged
American cohort [35] and in Mexican Americans of the
San Antonio Heart Study [36]. Moreover, a recent meta-
analysis of prospective studies clearly shows the graded
positive association of TG levels and all cause mortality risk
[37]. Finally, the ability of TG/HDL-C ratio to be a strong
independent predictor of all cause mortality was also ob-
served in acute coronary syndrome patients after coronary
revascularization [38] and in women with suspected myo-
cardial ischemia [39]. The positive association between TC,
non-HDL-C, TGs, TG/HDL-C and all cause mortality may
be partly attributed to their association with CVD, since
half of the deaths (51.1 %) were due to cardiovascular
deaths. However, a significant proportion of deaths were
also due to malignancies (30.0 %) and infections (7.8 %). A
worse lipid profile, especially raised TG levels in combin-
ation with low HDL-C, is indicative of metabolic syndrome
and insulin resistance which in turn associates with com-
mon cancers [40] and depression of the immune system
[41]. However, since the observed associations were inde-
pendent of diabetes, other, yet unknown mechanism may
underlie this relationship. Whether dyslipidemia is asso-
ciated with all cause mortality, irrespectively of co-
morbidities remains to be elucidated.
Evaluating the ability of lipid biomarkers to predict CVD
events it was confirmed that almost all were associated
with CVD risk independently from other cardiometabolic
risk factors (Table 2). It is therefore obvious that
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dyslipidemia is an important risk factor for CVD and
health policies, aiming initially on lifestyle changes,
should be implemented for the improvement of lipids’
metabolism which will inevitably lead to the reduction of
CVDs risk. However, it should also be noted that the
strength of the relationships between blood lipids/lipopro-
teins and CVD risk might be influenced by several
lifestyle-related factors such as dietary patterns [28, 42]
and socio-economic status [43]. For example, an increased
daily intake of antioxidant and anti-inflammatory vita-
mins, polyunsaturated fatty acids and phytochemicals, ei-
ther in the form of fruits, vegetables, fish and olive oil, or
as nutraceuticals and supplements, is able to favorably
modulate lipid levels and/or exert atheroprotective
properties, irrespective of lipid status, by preventing the
oxidizability of LDL [44, 45]. It is therefore, reasonable for
someone to assume that the predictive ability of lipid indi-
ces will be lower in populations with a high consump-
tion of the aforementioned dietary microconstituents.
Although these factors were taken into account here (the
MedDietScore reflects the daily intake of antioxidants and
phytochemicals in the form of fruits and vegetables),
cross-studies comparisons should be made with caution,
because of the heterogeneity of the lifestyle and socio-
economic status indices.
The importance of dyslipidemia is magnified by the fact
that the independent associations of the aforementioned
lipid indices with CVD risk were observed in a mildly dyli-
pidemic cohort, as the current one, indicating the graded
nature of the associations even around nearly normal
values. One of the main goals of the present analysis was to
reveal the best lipid biomarkers for accurate CVD risk pre-
diction. Indentifying better predictors for a disease is of
major importance for the correct disease management at
individual, as well as at population level. However, it is in-
teresting to see that numerous articles and book chapters
on CVD epidemiology and prevention start with “… cardio-
vascular disease is the main cause of death and disability,
and … dyslipidemia is the trigger of atherosclerotic process
that underlies CVD development”; although this is true, the
potential CVD candidate still remains under-estimated be-
cause of various reasons, the dyslipidemias are the most
varied and there is a need to better diagnosing and treating
dyslipidemia than prescribing lipid-lowering drugs [46].
Among all lipid indices measured in this study, the ratio of
apoB/apoA1 demonstrated the best correct reclassification
ability followed by non-HDL-C and TC/HDL-C ratio. Re-
cent large prospective studies have shown that apoB is a
better indicator of CVD risk than LDL-C [47, 48]. This is
because apoB levels are a direct estimate of the atherogenic
particles namely VLDL, IDL and LDL which all carry one
molecule of apoB. The superiority of apoB against LDL-C
as a CVD risk biomarker is more intense in populations
which are characterized by insulin resistance and metabolic
syndrome features. The apoB and LDL-C levels of those
populations are discordant, due to the predominance of
small dense LDL particles which contain less cholesterol
than normal [49]. Therefore, the LDL-C levels of those
populations may underestimate the real burden of the
atherogenic particles. For similar reasons apoA1 is a better
reflection of both HDL levels and functionality since the
dense HDL3 subfraction along with pro-atherogenic HDL
particles contain less apoA1 molecules [15]. In our study
neither apoB nor apoA1 could not achieve a high cNRI,
however their ratio (apoB/apoA1) was proved to have the
best correct reclassification ability. The apoB/apoA1 ratio
is actually an improved alternative to the TC/HDL-C ratio
and its predictive ability for CVDs has been demonstrated
before [50]. However, taking into account that: a) both TC/
HDL-C and non-HDL-C show similar cNRIs with apoB/
apoA1 ratio (Table 3), b) TC/HDL-C and non-HDL-C are
calculated from standard lipid markers with no additional
cost, c) the apoB and apoA1 measurements requires add-
itional cost, d) the application of apoB and apoA1 measure-
ments into routine clinical practise and prediction models
requires a time-consuming and costly education of the cli-
nicians, the incorporation of the apoB/apoA1 ratio into the
daily practise is not justified, especially in countries under a
financial crisis, like Greece.
Strengths and limitations
The follow-up period of the study is quite long and the
sample is representative of an urban Greek population.
The panel of lipid indices, evaluated for their ability to pre-
dict CVD, was wide including both traditional and novel
biomarkers. The models included a wide array of CVD risk
determinants strengthening by this way the independent
associations observed. Concerning the limitations of the
study, the baseline evaluation was performed once, using
questionnaires for lifestyle evaluation and, thus, may be
prone to measurement errors. The sample of the study
consisted of an urban population which cannot repre-
sent the total Greek population living in rural regions,
too. The relatively small number of deaths and CVD
events prevented from conducting sub-group analysis.
Finally, no information on the use of dietary supplements
and nutraceuticals was collected for the baseline examin-
ation of the ATTICA study, although, it is believed that, at
that time, its use was not very popular, especially, on
healthy individuals.
Conclusion
In conclusion, this cohort study of CVD epidemiology in
Greece demonstrated that elevated levels of lipid bio-
markers are independently associated with all-cause mor-
tality as well as CVD risk. These results suggest that,
similarly to other North American and European popula-
tions, dyslipidemia is a strong independent risk factor for
Nomikos et al. Lipids in Health and Disease  (2015) 14:108 Page 7 of 9
a Mediterranean population, too. The ratio of apoB/
apoA1, followed by non-HDL-C, demonstrated the best
correct classification ability of CVD risk, an observation
that may be prone useful in better identifying the future
CVD candidate at population level. Taking into account
the difficulties and cost of a routine determination of both
apoB and apoA1, the ability of non-HDL-C to improve
risk stratification should be further evaluated. Since there
is a large amount of data about the major causes of CVD,
and there is unequivocal evidence that risk factor modifi-
cation can reduce mortality, increase life expectancy and
quality of life, there is a need to be able to correctly esti-
mate CVD risk and plan effective, evidence based, public
health strategies.
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